Co-Diagnostics (CODX) Projected to Announce Earnings on Tuesday

Co-Diagnostics (NASDAQ:CODX) will likely be issuing its Q3 2026 results after the market closes on Tuesday, November 10th. Analysts expect Co-Diagnostics to announce earnings of ($1.25) per share and revenue of $0.17 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:30 PM ET.

Co-Diagnostics (NASDAQ:CODX) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.46) EPS for the quarter, beating analysts’ consensus estimates of ($3.00) by $1.54. Co-Diagnostics had a negative net margin of 6,531.77% and a negative return on equity of 210.99%. The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.13 million.

Co-Diagnostics Stock Performance

Shares of CODX stock opened at $0.26 on Friday. Co-Diagnostics has a 52-week low of $0.24 and a 52-week high of $13.54. The company has a market capitalization of $2.44 million, a PE ratio of -0.02 and a beta of 3.15. The business’s fifty day moving average is $0.89 and its 200 day moving average is $2.15.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on CODX shares. Weiss Ratings upgraded Co-Diagnostics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, October 27th. Maxim Group upgraded Co-Diagnostics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 18th. Finally, Wall Street Zen raised Co-Diagnostics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $45.00.

Co-Diagnostics Company Profile

Co-Diagnostics, Inc is a molecular diagnostics company that develops and commercializes diagnostic tests and laboratory technologies. Based in Salt Lake City, Utah, the company focuses on assays that detect genetic material from infectious diseases and other medical conditions.

The company’s core technology is its CoPrimer platform, which is designed to support the development of molecular tests using specialized primer technology. Products associated with the platform include the Logix Smart line of real-time polymerase chain reaction (PCR) assays, covering applications such as respiratory and other infectious diseases.